Stocks Fall On Retail Sales, Higher Oil
Stocks fell on Wednesday after
oil rebounded.
Early on, traders balanced a weak retail
sales report with good earnings from Lehman Brothers, but later in the session
the indices slid, closing near the lows.
August retail sales fell 2.1% in August–the
biggest drop in almost four years. Lehman Brothers
(
LEH |
Quote |
Chart |
News |
PowerRating) beat by 0.59
and beat on revenues. Profit rose 74% on higher M&A profits and increased debt
origination. Crude inventories fell by 6.6 million barrels, sending prices
higher. Crude oil rose 3% to close at $65.05.
Delta Airlines
(
DAL |
Quote |
Chart |
News |
PowerRating) and Northwest
Airlines
(
NWAC |
Quote |
Chart |
News |
PowerRating) may file for bankruptcy as early as today, The New
York Times reports.
Baidu.com
(
BIDU |
Quote |
Chart |
News |
PowerRating) fell over $32 on two
brokerage firms’ initial coverage. Goldman Sachs and Piper Jaffray both
initiated coverage of BIDU with underperform ratings. . Goldman analyst Anthony
Noto values the stock at $27.
ETrade
(
ET |
Quote |
Chart |
News |
PowerRating) reported daily average
trades (DARTs) rose 37% last from the same period a year ago.
Strong Sectors were: Gold
(
XAU |
Quote |
Chart |
News |
PowerRating)
+3.92% Oil Services
(
OSX |
Quote |
Chart |
News |
PowerRating) +1.33%
Weak sectors were:
Internet
(
GIN |
Quote |
Chart |
News |
PowerRating)
-1.60% Retail
(
RLX |
Quote |
Chart |
News |
PowerRating) -1.25%
|
|
-52.54 | 10,544.90 |
| -22.42 | 2149.33 | |
| -4.04 | 1227.16 |
Stocks in the news:
Amerisourcebergen
(
ABC |
Quote |
Chart |
News |
PowerRating) was upgraded
to Buy at UBS, with at $92 price target.
Google
(
GOOG |
Quote |
Chart |
News |
PowerRating) will begin its shelf
offering share sale after the market close today, Bloomberg reports. The company
said it expects to net $4.11 billion from the 14.16 million Class A shares.
Genentech
(
DNA |
Quote |
Chart |
News |
PowerRating) said a Phase II study
showed Herceptin with chemotherapy improved survival rates in women with early
stage breast cancer.
OSI Pharmaceuticals
(
OSIP |
Quote |
Chart |
News |
PowerRating) said an
FDA panel will recommend Tarceva for approval.
Abbot Lab’s
(
ABT |
Quote |
Chart |
News |
PowerRating) CEO Miles White
offered an upbeat forecast for 2007 and reaffirmed $0.56 – $0.58 for Q3 and
$2.47 – $2.53 for 2005 full-year earnings.
Teva Pharmaceuticals
(
TEVA |
Quote |
Chart |
News |
PowerRating) received FDA approval for Leflunomide
tablets for treatment of rheumatoid arthritis.
Brice Wightman